MS Australia is a national not-for-profit organisation dedicated to improving the lives of those affected by multiple sclerosis. Its remit includes supporting research for...
Jacqueline Hoogendam, JPND’s newly elected Vice-Chair and Executive Board member talks about JPND’s past and present strategies in its outreach campaign within and beyond Europe.
It is now well-known that the virus can create severe respiratory issues - but the impact of COVID on the brain is an equally important, unanswered question.
Research has found that low-intensity transcranial ultrasound stimulation can modulate brain activity and behaviours, supporting the observations of psychiatric conditions.
Professor Olivier Braissant, believes there is hope for the treatment of creatine deficiency thanks to new genetic disease research - here, he tells us all about the recent developments.
A new study finds the exact molecular mechanism that turns acute pain into chronic pain - a condition that leads to the use of opioids and often, lifelong addiction.
The study, published in PLoS Biology, looked at the neurotransmitter in the brain that calculates whether to pursue a task - in other words, motivation.
Dr Lynn Woods, Professor in the Department of Doctoral Programs, School of Nursing, Azusa Pacific University, describes Latinx with dementia and in this respect, why culture matters.
Professor Mogens Hørder, PPI expert, JPND’s management board member and representative of member state Denmark, discusses how Patient and Public Involvement (PPI) is at the heart of neurodegenerative disease research.
Chief Executive of the Huntington’s Disease Association, Cath Stanley, maps out the charities ongoing work to support its community, despite the COVID-19 pandemic.
Indiana University School of Medicine researchers are attempting to use magnetic nanoparticles to develop a cure for neurological disorders from epilepsy to Alzheimer's - without any invasive or genetic treatment.
